Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Reports Solid Q2 Financials

publication date: Aug 14, 2008

WuXi PharmaTech Inc., the Shanghai-based CRO, announced its Q2 financial results, showing that the company increased its revenues 134% to $70.8 million and enjoyed an 81% rise in non-GAAP net income, which came in at $15.5 million or 21 cents per ADS. The results were higher than analysts’ estimates. In the conference call, WuXi dodged questions about the performance of its AppTec acquisition and dangled the prospect of a big contract in the future. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital